Beatriz Moiraghi

3.5k total citations · 1 hit paper
42 papers, 2.1k citations indexed

About

Beatriz Moiraghi is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Beatriz Moiraghi has authored 42 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Hematology, 39 papers in Genetics and 15 papers in Rheumatology. Recurrent topics in Beatriz Moiraghi's work include Chronic Myeloid Leukemia Treatments (37 papers), Chronic Lymphocytic Leukemia Research (31 papers) and Eosinophilic Disorders and Syndromes (15 papers). Beatriz Moiraghi is often cited by papers focused on Chronic Myeloid Leukemia Treatments (37 papers), Chronic Lymphocytic Leukemia Research (31 papers) and Eosinophilic Disorders and Syndromes (15 papers). Beatriz Moiraghi collaborates with scholars based in Argentina, France and Germany. Beatriz Moiraghi's co-authors include Andreas Hochhaus, Jörge E. Cortes, Hagop M. Kantarjian, Ricardo Pasqüini, Michele Baccarani, Hirohisa Nakamae, Charles Chuah, M. Brigid Bradley‐Garelik, Chao Zhu and Manuel Ayala and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Beatriz Moiraghi

40 papers receiving 2.0k citations

Hit Papers

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phas... 2010 2026 2015 2020 2010 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
    2010 1.1k citations Hagop M. Kantarjian, Neil P. Shah et al. New England Journal of Medicine profile →

Peers

Beatriz Moiraghi
Valentín García‐Gutiérrez Spain
Concepción Boqué Spain
Philipp D. le Coutre Germany
M. Brigid Bradley‐Garelik United States
Philippe Rousselot France
Franck E. Nicolini France
P. Le Coutre Germany
Anna Turkina Russia
Saengsuree Jootar Thailand
Lydia Wunderle Germany
Valentín García‐Gutiérrez Spain
Beatriz Moiraghi
Citations per year, relative to Beatriz Moiraghi Beatriz Moiraghi (= 1×) peers Valentín García‐Gutiérrez

Countries citing papers authored by Beatriz Moiraghi

Since Specialization
Citations

This map shows the geographic impact of Beatriz Moiraghi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beatriz Moiraghi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beatriz Moiraghi more than expected).

Fields of papers citing papers by Beatriz Moiraghi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beatriz Moiraghi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beatriz Moiraghi. The network helps show where Beatriz Moiraghi may publish in the future.

Co-authorship network of co-authors of Beatriz Moiraghi

This figure shows the co-authorship network connecting the top 25 collaborators of Beatriz Moiraghi. A scholar is included among the top collaborators of Beatriz Moiraghi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beatriz Moiraghi. Beatriz Moiraghi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Moiraghi, Beatriz, Alicia Enrico, Romina Mariano, et al.. (2025). Evaluation of leukemic stem cell (CD26 +) in chronic myeloid leukemia patients with different molecular responses and in treatment-free remission. Clinical and Experimental Medicine. 25(1). 93–93. 1 indexed citations
2.
Moiraghi, Beatriz, et al.. (2025). Exploring the significance of MDM2 gene promoter variants in chronic myeloid leukemia. Leukemia Research. 149. 107644–107644. 1 indexed citations
3.
Deininger, Michael W., Jane Apperley, Christopher Arthur, et al.. (2024). Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC.. Journal of Clinical Oncology. 42(16_suppl). 6501–6501.
4.
5.
Lev, Paola R., Nora P. Goette, Federico Sackmann, et al.. (2023). High cell-free DNA is associated with disease progression, inflammasome activation and elevated levels of inflammasome-related cytokine IL-18 in patients with myelofibrosis. Frontiers in Immunology. 14. 1161832–1161832. 4 indexed citations
6.
Moiraghi, Beatriz, et al.. (2023). Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy Analysis. Clinical Lymphoma Myeloma & Leukemia. 24(3). 158–164. 1 indexed citations
7.
Moiraghi, Beatriz, et al.. (2022). P715: MULTICENTER OBSERVATIONAL STUDY OF PONATINIB IN CML PATIENTS IN ARGENTINA. REAL-WORLD EXPERIENCE.. HemaSphere. 6. 610–611. 2 indexed citations
8.
Pavlovsky, Carolina, Kátia Bórgia Barbosa Pagnano, Michele Bianchini, et al.. (2021). Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel. Blood Advances. 5(23). 4855–4863. 13 indexed citations
9.
Furtado, Carolina, Patricio Yankilevich, Beatriz Moiraghi, et al.. (2021). miRNome profiling of LSC-enriched CD34+CD38−CD26+ fraction in Ph+ CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool. Frontiers in Pharmacology. 11. 612573–612573. 10 indexed citations
10.
Oyarzún, Cecilia P. Marín, Ana C. Glembotsky, Nora P. Goette, et al.. (2020). Platelet Toll-Like Receptors Mediate Thromboinflammatory Responses in Patients With Essential Thrombocythemia. Frontiers in Immunology. 11. 705–705. 42 indexed citations
11.
Hughes, Timothy P., Carla Boquimpani, Naoto Takahashi, et al.. (2018). ENESTop 144-Week Update: Long-Term Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib. Clinical Lymphoma Myeloma & Leukemia. 18. S222–S222. 3 indexed citations
12.
Moiraghi, Beatriz, et al.. (2016). TP53 codon 72 polymorphism predicts chronic myeloid leukemia susceptibility and treatment outcome. Blood Cells Molecules and Diseases. 59. 129–133. 10 indexed citations
13.
Oyarzún, Cecilia P. Marín, Agostina Carestia, Paola R. Lev, et al.. (2016). Neutrophil extracellular trap formation and circulating nucleosomes in patients with chronic myeloproliferative neoplasms. Scientific Reports. 6(1). 38738–38738. 58 indexed citations
14.
Moiraghi, Beatriz, et al.. (2016). GSTM1 and GSTP1 , but not GSTT1 genetic polymorphisms are associated with chronic myeloid leukemia risk and treatment response. Cancer Epidemiology. 44. 16–21. 21 indexed citations
15.
Moiraghi, Beatriz, et al.. (2015). MDR1/ABCB1 gene polymorphisms in patients with chronic myeloid leukemia. Blood Research. 50(3). 154–154. 10 indexed citations
16.
17.
Larson, Richard A., Andreas Hochhaus, Timothy P. Hughes, et al.. (2012). Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 26(10). 2197–2203. 323 indexed citations
18.
19.
Kantarjian, Hagop M., Neil P. Shah, Andreas Hochhaus, et al.. (2010). Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. New England Journal of Medicine. 362(24). 2260–2270. 1103 indexed citations breakdown →
20.
Brasi, Carlos Daniel De, et al.. (2010). BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia. Blood Cells Molecules and Diseases. 45(3). 192–196. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Valentín García‐Gutiérrez Breakdown of academic impact, for papers by Concepción Boqué Breakdown of academic impact, for papers by Philipp D. le Coutre Breakdown of academic impact, for papers by M. Brigid Bradley‐Garelik Breakdown of academic impact, for papers by Philippe Rousselot Breakdown of academic impact, for papers by Franck E. Nicolini Breakdown of academic impact, for papers by P. Le Coutre Breakdown of academic impact, for papers by Anna Turkina Breakdown of academic impact, for papers by Saengsuree Jootar Breakdown of academic impact, for papers by Lydia Wunderle
Rankless by CCL
2026